The 2021 American Association for the Study of Liver Diseases (AASLD) practice guidance on ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS) emphasizes albumin as a therapeutic intervention in decompensated cirrhosis, used to modify clinically meaningful outcomes rather than to correct serum albumin levels. Albumin is described as a multifunctional protein with oncotic, anti-inflammatory, antioxidant, and endothelial-stabilizing effects, and its clinical use is directed toward the prevention and treatment of circulatory dysfunction and renal injury. [1]
In patients with tense or grade 3 ascites, large-volume paracentesis (LVP) is recommended as first-line therapy, with intravenous (IV) hyperoncotic human albumin administered to prevent postparacentesis circulatory dysfunction (PPCD). Albumin is particularly indicated when more than 5 L of ascitic fluid are removed, since smaller-volume paracentesis is not typically associated with clinically significant hemodynamic instability. Although no formal dose-response trials exist, guideline-based practice supports administration of approximately 6-8 g of albumin per liter of ascites removed, with the intent of maintaining effective arterial blood volume and reducing the risk of circulatory dysfunction and renal impairment. In pediatric patients, management of ascites in cirrhosis follows similar physiologic principles but with weight-based dosing adjustments. Albumin infusion appears to reduce the risk of PPCD in children, which is highest when large volumes of ascites are removed or when fluid removal occurs at a rapid flow rate, based on limited pediatric data. Children undergoing LVP are generally given 25% albumin at doses of 0.5-1.0 g/kg, or approximately 6-8 g per liter of ascites removed, to maintain circulatory stability and reduce hemodynamic complications. [1]
In SBP, albumin is used in combination with antibiotics to improve survival and reduce renal failure. The benefit is most pronounced in patients with baseline renal dysfunction or more advanced hepatic decompensation. The widely adopted regimen is 1.5 g/kg on day 1 followed by 1 g/kg on day 3. In this setting, albumin is used as a physiologic therapy to prevent progression of acute kidney injury (AKI) and circulatory collapse during infection rather than as a laboratory-targeted intervention. In HRS-AKI, albumin is administered as part of combination therapy with vasoconstrictors. Initial treatment typically includes an albumin infusion of approximately 1 g/kg on day 1, followed by maintenance dosing during ongoing vasoconstrictor therapy, commonly around 40-50 g/day. The therapeutic goal is to expand effective arterial blood volume, improve renal perfusion, and support hemodynamic stability, with dosing adjusted based on clinical response rather than serum albumin concentration. [1]
Beyond these acute indications, albumin has been studied in long-term outpatient use for patients with decompensated cirrhosis and refractory ascites. In the ANSWER trial, scheduled albumin infusions in patients with diuretic-responsive ascites were associated with improved survival and reduced mortality over prolonged follow-up. In contrast, the MACHT trial demonstrated hemodynamic improvements without a reduction in major clinical outcomes or mortality. These findings highlight uncertainty regarding optimal long-term dosing strategies, cost-effectiveness, and patient selection, and current guidance does not recommend routine chronic albumin administration outside of specific indications. [1]
Albumin has also been evaluated in related complications such as hyponatremia and hepatic hydrothorax. In hypervolemic hyponatremia, albumin may be used alongside fluid restriction and diuretic adjustment to support circulatory function, particularly in more severe cases. In hepatic hydrothorax, albumin may be administered in conjunction with LVP to improve hemodynamic stability, although evidence for routine use in this setting remains limited. Overall, the AASLD guidance positions albumin as a targeted therapeutic agent used in specific high-risk complications of cirrhosis, namely LVP, SBP, and HRS-AKI, where its benefit derives from improvement in circulatory function and prevention of renal dysfunction rather than correction of serum albumin levels. [1]
Previous AASLD guidance published in 2012 for the mnagement of adult patients with ascites due to cirrhosis similarly states that post-paracentesis albumin infusion may not be necessary for a single paracentesis of less than 4 to 5 L. For LVP, an albumin infusion of 6-8 g per liter of fluid removed appears to improve survival and is recommended. In patients with ascitic fluid polymorphonuclear leukocyte counts ≥250 cells/mm³ and clinical suspicion of SBP who also have serum creatinine >1 mg/dL, blood urea nitrogen >30 mg/dL, or total bilirubin >4 mg/dL, albumin 1.5 g/kg body weight within 6 hours of detection, followed by 1.0 g/kg on day 3 is recommended. In type HRS, albumin infusion in combination with vasoactive drugs such as octreotide and midodrine should be considered, and albumin infusion in combination with norepinephrine should also be considered in the intensive care unit (ICU) setting. [2], [3]
The British Association for the Study of the Liver (BASL) guidelines on the management of ascites in cirrhosis recommend human albumin solution (HAS) as a therapeutic intervention following paracentesis and in SBP, with dosing specified by clinical scenario. After LVP of >5 L, albumin (as 20% or 25% solution) should be infused at a dose of 8 g albumin per liter of ascites removed. After paracentesis of <5 L, albumin can be considered at the same dose in patients with acute-on-chronic liver failure (ACLF) or those at high risk of post-paracentesis AKI. In patients with SBP and an increased or rising serum creatinine, albumin is recommended at 1.5 g/kg within 6 hours of diagnosis, followed by 1 g/kg on day 3. Overall, BASL positions HAS as a scenario-specific therapy in cirrhosis with dosing determined by clinical indication such as LVP and SBP. [4]
Lastly, a 2021 review article on long-term albumin infusion in decompensated cirrhosis describes established indications of albumin in decompensated cirrhosis. SBP is defined by >250 polymorphonuclear cells/mm³ or positive ascitic fluid cultures, and albumin infusion was shown in a randomized trial to reduce renal impairment (33% vs. 10%), inpatient mortality (29% vs. 10%), and 3-month mortality (41% vs. 22%) when given with antibiotics. In high-risk patients (serum bilirubin ≥4 mg/dL or creatinine ≥1 mg/dL), benefit was confirmed in meta-analysis, while low-risk SBP shows low pooled rates of renal impairment (2.8%) and death (3.8%), with a number needed to treat of 45 and 27, respectively. For LVP, post-paracentesis circulatory dysfunction occurs in 17.1%-72.7% of cases and is associated with renal impairment and mortality, and albumin at 6–8 g/L of ascitic fluid removed reduces post-paracentesis circulatory dysfunction and mortality, particularly when >5 L is removed, with most studies using 6-8 g of 20% albumin per liter drained. In HRS, most evidence is in HRS-AKI, where albumin is used with vasoconstrictors such as terlipressin, norepinephrine, or octreotide, typically at 20-40 g/day titrated to fluid status. Combination therapy reverses HRS-AKI in up to ~56% of patients, though adverse events occur in up to 43%, and continuous terlipressin may reduce complications (35% vs 62%) without loss of efficacy. Despite reversal of HRS-AKI in up to ~60%, meta-analyses show no clear mortality benefit versus placebo. In hepatic encephalopathy (HE), albumin has been studied for both prevention and treatment; prevention after transjugular intrahepatic portosystemic shunt (TIPS) showed no benefit, while treatment studies used regimens such as 1.5 g/kg/day until resolution or up to 10 days, with mixed outcomes including improved HE grade, shorter hospitalization (6.4 vs 8.6 days), and reduced mortality (18% vs. 32%), but inconsistent findings across trials and no guideline endorsement for routine use. In ACLF, albumin has been studied as adjunct therapy, including in infected patients, where resolution of ACLF was higher with albumin (82.3% vs. 33.3%), but mortality was unchanged. Overall, the review concludes that established indications for albumin infusion in decompensated cirrhosis remain SBP, LVP, and HRS, with dosing defined by clinical scenario, while evidence for broader or long-term use remains heterogeneous and not yet definitive. [5]